STL Index for: Irina Turchin

Topical ruxolitinib shows promise in various dermatological conditions, including atopic dermatitis, vitiligo, psoriasis, and lichen planus, with a favorable safety profile compared to oral JAK inhibitors. However, its effectiveness in alopecia areata remains inconclusive.

Results from multiple studies have shown promising response rates, and extracorporeal photopheresis has an overall excellent safety profile with very few adverse events reported.